Participants 0 62 4
Targeting alpha-7 nicotinic neurotransmission in schizophrenia
Participants 204 241 3
 cognitive impairment in schizophreni
Participants 738 838 5
 in schizophrenia patients with negative symptoms who were receiving second generation antipsychotic
Participants 840 930 7
 Forty-three subjects received galantamine and CDP-choline or matching placebos for 16week
